

Table S5. Demographics of patients with wild-type (wt) and mutant (mut) *ATRX*.

		Wt (n = 380)	Mut (n = 67)	Unknown (n = 155)	<i>P</i>
Median age		58 (19-92)	49 (37-68)	60 (20 – 90)	.17
Female		212 (55.8)	47 (70.1)	91 (58.7)	.09
Race	Asian	80 (21.1)	17 (25.4)	18 (11.6)	< .001
	Black	14 (3.7)	1 (1.5)	10 (6.5)	
	Hispanic	46 (12.1)	7 (10.4)	40 (25.8)	
	White	221 (58.2)	42 (62.7)	84 (54.2)	
	Others	19 (5.0)	0 (0)	3 (1.9)	
PS	0-1	329 (86.6)	63 (94.0)	130 (83.9)	.13
	2-4	39 (10.3)	2 (3.0)	15 (9.7)	
	Unknown	12 (3.2)	2 (3.0)	10 (6.5)	
CCI		1 (0-9)	1 (0-7)	0 (0-6)	<0.001
Treatment	Yes	296 (77.9)	56 (83.6)	122 (78.7)	.58
	No	84 (22.1)	11 (16.4)	33 (21.3)	
Histology	LMS	85 (22.4)	34 (50.7)	55 (35.5)	< .001
	UPS	96 (25.3)	14 (20.9)	26 (16.8)	
	LPS	52 (13.7)	5 (7.5)	21 (13.5)	
	Others	147 (38.7)	14 (20.9)	53 (34.2)	
<i>RB1</i>	wt	317 (83.4)	30 (44.8)	124 (80.0)	< .001
	mut	63 (16.6)	37 (55.2)	31 (20.0)	
<i>TP53</i>	wt	211 (55.5)	14 (20.9)	81 (52.3)	< .001
	mut	169 (44.5)	53 (79.1)	74 (47.7)	
<i>CDKN2A</i>	wt	281 (73.9)	60 (89.6)	122 (78.7)	.017
	mut	99 (26.1)	7 (10.4)	33 (21.3)	
<i>PTEN</i>	wt	349 (91.8)	58 (86.6)	138 (89.0)	.30
	mut	31 (8.2)	9 (13.4)	17 (11.0)	

Note: PS, performance status; CCI, Charlson comorbidity index; LMS, leiomyosarcoma; UPS, undifferentiated pleomorphic sarcoma; LPS, liposarcoma. The number inside the parenthesis represents percent except for median age.